Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients
Article first published online: 25 JAN 2014
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Acta Neurologica Scandinavica
Volume 130, Issue 1, pages 46–52, July 2014
How to Cite
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients. Acta Neurol Scand 2014: 130: 46–52. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd., , , , , , , , .
- Issue published online: 10 JUN 2014
- Article first published online: 25 JAN 2014
- Manuscript Accepted: 22 NOV 2013
- Merck Serono GmbH
- Association pour la Recherche sur la Sclérose En Plaques (ARSEP)
- experimental autoimmune encephalomyelitis;
- multiple sclerosis;
- Th17 cells;
There is convergent evidence for an important role of interleukin-16 (IL-16) in the pathogenesis of multiple sclerosis (MS). IL-16 serves as a chemoattractant for different immune cells that are involved in developing lesions. Here, we compared IL-16 levels of MS patients and controls and addressed the long-term effect of IFN-β, the most common immunomodulatory MS therapy, on IL-16 serum levels in MS patients over 2 years. Beyond this, we analysed the expression of IL-16 in two CD4+ T-cell subsets, Th1 and Th17 cells, which are important autoimmune mediators and affected by IFN-β treatment, derived from myelin-specific T-cell transgenic mice.
Materials and methods
IL-16 serum levels of 17 controls and of 16 MS patients before therapy and at months 1, 2, 3, 6, 9, 12 and 24 during IFN-β1a therapy were determined by ELISA. MRI was performed before therapy, at months 12 and 24. IL-16 expression of in vitro differentiated murine myelin oligodendrocyte glycoprotein (MOG)-specific Th1 and Th17 cells was quantified by real-time PCR.
Before therapy, MS patients showed significantly elevated IL-16 levels compared with controls irrespective of disease activity determined by MRI. Therapy with IFN-β1a led to a significant linear decrease in IL-16 serum levels beginning after 2 months. MOG-specific Th17 cells expressed more IL-16 than Th1 cells.
Reduction in increased IL-16 levels may be of relevance for the therapeutic effect of IFN-β1a in MS. Easily accessible IL-16 serum levels hold a potential as biomarker of treatment efficacy in MS.